Shingrix received green signal from the FDA on October 20, 2017 for the prevention of shingles (herpes zoster) in adults aged 50 years and older.Developed by GlaxoSmithKline plc, Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses.The only other shingles vaccine approved for use in the United States is Merck & Co. Inc.'s (MRK) Zostavax, which is given as a single dose by an injection under the skin. Market intelligence firm Evaluate estimates Shingrix could reach more than $1 billion in yearly sales by 2022.Shingrix, which is expected to be available shortly, will cost $280 per patient for two doses. The vaccine has also received positive recommendation from CDC's Advisory Committee on immunization practices as preferred vaccine for prevention of Shingles.